Frankfurt - Delayed Quote EUR

Aspen Pharmacare Holdings Limited (LDZU.F)

Compare
8.65
+0.05
+(0.58%)
At close: January 22 at 8:07:12 AM GMT+1
Loading Chart for LDZU.F
DELL
  • Previous Close 8.60
  • Open 8.65
  • Bid 8.60 x --
  • Ask --
  • Day's Range 8.65 - 8.65
  • 52 Week Range 8.25 - 12.70
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) 3.939B
  • Beta (5Y Monthly) 0.58
  • PE Ratio (TTM) 16.96
  • EPS (TTM) 0.51
  • Earnings Date Mar 4, 2025
  • Forward Dividend & Yield 0.19 (2.19%)
  • Ex-Dividend Date Sep 20, 2024
  • 1y Target Est --

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general, local, and regional anesthetic; low molecular weight heparin; regional and spinal anesthetic; and opioid analegesic under the Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine brand names. It also offers such as sleeping aid, thyroid hormone, immunosuppressant, iron supplement, analgesic anti-inflammatory, and hormone replacement therapy under the Circadin, Eltroxin, Foxair, Imuran, Maltofer, Mybulen, and Ovestin brand names. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

www.aspenpharma.com

8,867

Full Time Employees

June 30

Fiscal Year Ends

Recent News: LDZU.F

View More

Performance Overview: LDZU.F

Trailing total returns as of 1/22/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

LDZU.F
1.17%
All Share Index
0.84%

1-Year Return

LDZU.F
4.99%
All Share Index
16.51%

3-Year Return

LDZU.F
21.50%
All Share Index
13.12%

5-Year Return

LDZU.F
27.33%
All Share Index
46.02%

Compare To: LDZU.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LDZU.F

View More

Valuation Measures

Annual
As of 1/21/2025
  • Market Cap

    3.87B

  • Enterprise Value

    5.12B

  • Trailing P/E

    16.76

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.65

  • Price/Book (mrq)

    0.87

  • Enterprise Value/Revenue

    2.21

  • Enterprise Value/EBITDA

    9.98

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.85%

  • Return on Assets (ttm)

    4.06%

  • Return on Equity (ttm)

    5.15%

  • Revenue (ttm)

    44.71B

  • Net Income Avi to Common (ttm)

    4.4B

  • Diluted EPS (ttm)

    0.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.34B

  • Total Debt/Equity (mrq)

    42.96%

  • Levered Free Cash Flow (ttm)

    354.12M

Research Analysis: LDZU.F

View More

Company Insights: LDZU.F

Research Reports: LDZU.F

View More

People Also Watch